



Please type a plus sign (+) inside this box → **[+]**

#8 pg 10/03/02

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

1632

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/844,915
		Filing Date	April 27, 2001
		First Named Inventor	Robbins
		Group Art Unit	1632
		Examiner Name	Chen, L.
Total Number of Pages in This Submission		Attorney Docket Number	AP32737 072396.0225

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	BakerBotts LLP 30 Rockefeller Plaza New York, NY 10112
Signature	<i>Carmella L. Stephens</i>
Date	September 23, 2002

Att Name: Carmella L. Stephens
PTO Reg: 41,328

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: **September 23, 2002**

Typed or printed name	Carmella L. Stephens		
Signature	<i>Carmella L. Stephens</i>	Date	September 23, 2002

BAKER BOTTS



Attorney Docket Number: AP32737 072396.0225

Title:

THE USE OF TOLEROGENIC DENDRITIC CELLS FOR ENHANCING THE TOLEROGENICITY IN A HOST AND METHODS FOR MAKING THE SAME

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

Use Space Below for Additional Information:



AP32737 072396.0225

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robbins et al.

Serial No.: 09/844,915

Examiner: Chen, L.

Filing Date: April 27, 2001

Group Art: 1632

Title of Invention: THE USE OF TOLEROGENIC DENDRITIC CELLS FOR
ENHANCING THE TOLEROGENICITY IN A HOST AND METHODS
FOR MAKING THE SAME

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231

September 23, 2002
Date of Deposit

Carmella L. Stephens
Attorney Name

41,328
PTO Registration No.

Carmella L. Stephens
Signature

September 23, 2002
Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated August 23, 2002 in the above-identified application in which the Examiner issued a restriction requirement. The Examiner has placed the claims into two groups as follows:

Group I: Claims 1-34, 41-59, and 63-65 directed to (1) a tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF- κ B binding sites, (2) a method of producing the dendritic cell, and (3) a kit for enhancing tolerogenicity in a host; and

Group II: Claims 35-40, 60-62, 66 and 67 directed to a method for treating diabetes in a mammalian host comprising administering to the host dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF- κ B binding site.

In response to the restriction requirement, Applicants elect to prosecute Claims 1-34, 41-59, and 63-65 of Group I, to be examined in this application without prejudice to the prosecution of the subject matter of non-elected claims in other patent applications.

Applicants believe that there is no fee due with the filing of this paper. However, if any fee is due, or if any overpayment has been made, in connection with the filing of this response, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377. Duplicate copies of this sheet are enclosed.

Respectfully submitted,

Carmella L. Stephens
Rochelle K. Seide
Patent Office Reg. No. 32,300

Carmella L. Stephens
Patent Office Reg. No. 41,328

Alicia A. Russo
Patent Office Reg. No. 46,192

Attorneys for Applicants
(212) 408-2500